Chang-Qing Wei

Title: Innovations of Chang-Qing Wei in SH2 Domain Binding Inhibitors

Introduction

Chang-Qing Wei is a notable inventor based in Ottawa, Canada. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit SH2 domain binding. With a total of 2 patents, his work has implications for cancer treatment and pharmaceutical compositions.

Latest Patents

Chang-Qing Wei's latest patents focus on SH2 domain binding inhibitors. These patents disclose compounds designed to inhibit SH2 domain binding, which is crucial for various cellular processes. The compounds include a formula where R is a lipophile, and in combination with the phenyl ring, forms a phenylphosphate mimic group. The compounds are engineered to enhance binding affinity with SH2 domain proteins. Additionally, the patents describe pharmaceutical compositions and methods for inhibiting SH2 domains from binding with phosphoproteins, as well as methods for treating breast cancer.

Career Highlights

Chang-Qing Wei is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to significant advancements in medical research and drug development.

Collaborations

Some of his notable coworkers include Terrence R Burke, Jr and Yang Gao. Their collaborative efforts have furthered research in the field and enhanced the impact of their findings.

Conclusion

Chang-Qing Wei's innovative work in SH2 domain binding inhibitors showcases his commitment to advancing medical science. His contributions are vital for the development of new therapeutic strategies, particularly in cancer treatment.